Latest Market News

Next Science Limited is set to distribute approximately A$0.145 per share following the sale of its assets to OSARTIS GmbH, marking a significant step towards winding down its operations.

Bioxyne Limited has reported a record $17.2 million in quarterly revenue, driven by strong growth in its cannabis and psychedelics segments, alongside strategic international expansions including a Frankfurt dual listing and new manufacturing agreements.

Dubber Corporation Limited has signed a significant five-year contract with a major North American communications provider, while trimming costs and targeting operating cashflow breakeven in FY26.

Stockland announces a 9-cent unfranked dividend for the half-year ending December 2025, alongside a Dividend Reinvestment Plan priced at $5.47 per security. The DRP offers investors a 1% discount and new securities issued will rank equally from the issue date.

Greatland Resources capped off 2025 with robust gold and copper production at Telfer, generating $406 million in operating cash flow, while its Havieron feasibility study confirmed a world-class, low-cost gold-copper mine with a $4.2 billion pre-tax NPV.

Develop Global Limited reports strong December quarter progress with Woodlawn mine commissioning on track, a major contract win, and a significant value uplift at Sulphur Springs ahead of a mid-2026 investment decision.

LTR Pharma has marked a key milestone with over 1,000 SPONTAN prescriptions under Australia’s Special Access Scheme and is advancing clinical trials and US market preparations for its erectile dysfunction treatments.

Ampol Limited reports a robust fourth quarter Lytton Refiner Margin of US$15.14 per barrel, underpinning a strong preliminary FY25 earnings update with an expected EBIT of approximately $945 million.

Control Bionics has raised $3.8 million to fuel growth, forged a key distribution deal with Tobii, and integrated with Apple’s BCI protocol, while advancing its NeuroStrip and NeuroBounce platforms.

Bioxyne Limited has posted a record $17.2 million in quarterly revenue for Q2 FY26, driven by strong growth in its cannabis and psychedelics segments alongside strategic international expansions.

Tetratherix Limited (ASX, TTX) reports significant progress in clinical trials, strategic partnerships, and manufacturing capacity, positioning itself for near-term commercialisation and sustained innovation.

Coronado Global Resources reported a solid FY25 with increased saleable production and reduced mining costs, underpinned by key expansions and refinancing deals that set the stage for stronger cash flow in 2026.